Shi, Bingyang - Macquarie University

个人简介

With the award of a competitive Macquarie University Research Fellowship in 2014, I relocated to Macquarie Uni (MQ) to lead a new Brain Drug Delivery Group. There I chase my research dream and ambition to address one of the major challenges for brain disease therapy which is the successful delivery of therapeutic agents across the Blood Brain Barrier (BBB) – the BBB acts as a cellular barrier that prevents toxins, foreign materials and other dangerous molecules from entering the brain, however as a consequence this poses major challenges for getting therapeutic molecules into the brain. I contributed my expertise & knowledge to develop a new Blood-Brain-Barrier (BBB) penetration mechanism, as well as pioneering new strategies for brain drug delivery that led to an NHMRC Peter Doherty Fellowship (GNT1111822) and NHMRC-ARC Dementia Research Development Fellowship (GNT1111611) (Declined the former and took the Dementia one). In 2016, I discovered a novel glucose-transporter-mediated BBB penetration pathway and drug-controlled-release strategy in neuron, developing an effective brain delivery strategy (Glu-NPs; 2017) and attracting a Mason Foundation grant (GNT MAS2017F034) and NHMRC Project Grant (GNT1166024) for dementia therapy (both CIA; 2018). I lead a multidisciplinary team across MQ (myself, brain delivery; Dr Wright, Alzheimer’s disease (AD) biochemistry) and Western Sydney U (Dr. Chesworth, AD mouse behavior) for these funded projects. Inspired by the unique capabilities of natural cells, I developed another novel biomimetic brain delivery strategy (Bio-NPs) with outstanding therapeutic effects for brain tumor therapy, which led to Australian Government Endeavour Research Fellowship (Recipient ID:6917_2018) to support visit Harvard University for six months to explore the potential applications in brain metastatic brain cancer therapy. From 2019, I have been leading a 2nd multidisciplinary team across MQ, Henan province hospital, Huashan Hospital and Harvard Medical School for this project. In recognizing my significant contributions to my research program, I was awarded five competitive fellowships(Macquarie University Research Fellowship, NHMRC Peter Doherty Fellowship, Australian Government Endeavour Research Fellowship, NHMRC-ARC Dementia Research Development Fellowship and NHMRC Investigator Fellow (EL2)), many prestigious awards, eg, American Chem Society Rising star Award and MQ Early Career Researcher of the year in 2019.

研究领域

my research program is developing advanced brain drug delivery system to efficiently transport the therapeutic drug across BBB into Brain for preclinical brain disease therapy evaluation with three core research streams: 1) development of novel nanoparticle-based blood–brain barrier (BBB) penetration mechanisms; 2) development of brain delivery systems based on the BBB mechanisms discovered in stream 1; 3) preclinical evaluation of therapies for brain diseases based on the delivery systems developed in stream 2.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

A biomimetic nanomedicine targets orthotopic glioblastoma by combinatorial co-delivery of temozolomide and a methylguanine-DNA methyltransferase inhibitor. Wang, Y., Sun, Y., Geng, N., Zheng, M., Zou, Y. & Shi, B., 20 Sep 2022, (E-pub ahead of print) In: Advanced Therapeutics. 13 p., 2200095. Arsenic prodrug-mediated tumor microenvironment modulation platform for synergetic glioblastoma therapy. Yan, J., Hanif, S., Zhang, D., Ismail, M., Wang, X., Li, Q., Shi, B., Muhammad, P. & Wu, H., 17 Aug 2022, In: ACS Applied Materials and Interfaces. 14, 32, p. 36487-36502 16 p. Aspect ratio of PEGylated upconversion nanocrystals affects the cellular uptake in vitro and in vivo. Fu, L., Shi, B., Wen, S., Morsch, M., Wang, G., Zhou, Z., Mi, C., Sadraeian, M., Lin, G., Lu, Y., Jin, D. & Chung, R., 15 Jul 2022, In: Acta Biomaterialia. 147, p. 403-413 11 p. Biomimetic Dp44mT-nanoparticles selectively induce apoptosis in Cu-loaded glioblastoma resulting in potent growth inhibition. Ismail, M., Yang, W., Li, Y., Wang, Y., He, W., Wang, J., Muhammad, P., Chaston, T. B., Rehman, F. U., Zheng, M., Lovejoy, D. B. & Shi, B., Oct 2022, In: Biomaterials. 289, p. 1-14 14 p., 121760. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Zou, Y., Sun, X., Yang, Q., Zheng, M., Shimoni, O., Ruan, W., Wang, Y., Zhang, D., Yin, J., Huang, X., Tao, W., Park, J. B., Liang, X. J., Leong, K. W. & Shi, B., 22 Apr 2022, In: Science Advances. 8, 16, p. 1-14 14 p., eabm8011. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Zou, Y., Wang, Y., Xu, S., Liu, Y., Yin, J., Lovejoy, D. B., Zheng, M., Liang, X-J., Park, J. B., Efremov, Y., Ulasovand, L. & Shi, B., Aug 2022, In: Advanced Materials. 34, 33, p. 1-12 12 p., 2203958. Brain-targeted aggregation-induced-emission nanoparticles with near-infrared imaging at 1550 nm boosts orthotopic glioblastoma theranostics. Wang, J., Liu, Y., Morsch, M., Lu, Y., Shangguan, P., Han, L., Wang, Z., Chen, X., Song, C., Liu, S., Shi, B. & Tang, B. Z., 3 Feb 2022, In: Advanced Materials. 34, 5, p. 1-9 9 p., 2106082. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. He, W., Li, X., Morsch, M., Ismail, M., Liu, Y., Rehman, F. U., Zhang, D., Wang, Y., Zheng, M., Chung, R., Zou, Y. & Shi, B., 30 Mar 2022, In: ACS Nano. 16, 4, p. 6293-6308 16 p. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy. Ruan, W., Jiao, M., Xu, S., Ismail, M., Xie, X., An, Y., Guo, H., Qian, R., Shi, B. & Zheng, M., Nov 2022, In: Journal of Controlled Release. 351, p. 739-751 13 p. Brain-targeted polymersome codelivery of siRNA and temozolomide for effective glioblastoma chemo-RNAi synergistic therapy. Zheng, M., Yan, C., Yang, Q., Zhu, F., Du, Q., Xia, X., Morsch, M., Lee, A., Yin, J., Zou, Y. & Shi, B., Jul 2022, In: ChemPhysMater. 1, 3, p. 203-210 8 p. Brain-targeting metastatic tumor cell membrane cloaked biomimetic nanomedicines mediate potent chemodynamic and RNAi combinational therapy of glioblastoma. Zhang, D., Sun, Y., Wang, S., Zou, Y., Zheng, M. & Shi, B., 3 Oct 2022, (E-pub ahead of print) In: Advanced Functional Materials. 13 p. Carbon dots supported single Fe atom nanozyme for drug-resistant glioblastoma therapy by activating autophagy-lysosome pathway. Muhammad, P., Hanif, S., Li, J., Guller, A., Rehman, F. U., Ismail, M., Zhang, D., Yan, X., Fan, K. & Shi, B., Aug 2022, In: Nano Today. 45, p. 1-17 17 p., 101530. Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy. Rehman, F. U., Liu, Y., Yang, Q., Yang, H., Liu, R., Zhang, D., Muhammad, P., Liu, Y., Hanif, S., Ismail, M., Zheng, M. & Shi, B., May 2022, In: Journal of Controlled Release. 345, p. 696-708 13 p. Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. Ismail, M., Yang, W., Li, Y., Chai, T., Zhang, D., Du, Q., Muhammad, P., Hanif, S., Zheng, M. & Shi, B., Aug 2022, In: Biomaterials. 287, p. 1-13 13 p., 121608. The efficient regeneration of corneal nerves via tunable transmembrane signaling channels using a transparent graphene-based corneal stimulation electrode. Zheng, Z., Lin, M., Lu, W., Huang, P., Zheng, Y., Zhang, X., Yan, L., Wang, W., Lawson, T., Shi, B., Chen, S. & Liu, Y., 18 May 2022, In: Advanced Healthcare Materials. 11, 10, p. 1-8 8 p., 2101667. ALS/FTD-causing mutation in cyclin F causes the dysregulation of SFPQ. Rayner, S. L., Cheng, F., Hogan, A. L., Grima, N., Yang, S., Ke, Y. D., Au, C. G., Morsch, M., De Luca, A., Davidson, J. M., Molloy, M. P., Shi, B., Ittner, L. M., Blair, I., Chung, R. S. & Lee, A., 1 Jun 2021, In: Human Molecular Genetics. 30, 11, p. 971-984 14 p. Capturing functional two-dimensional nanosheets from sandwich-structure vermiculite for cancer theranostics. Ji, X., Ge, L., Liu, C., Tang, Z., Xiao, Y., Chen, W., Lei, Z., Gao, W., Blake, S., De, D., Shi, B., Zeng, X., Kong, N., Zhang, X. & Tao, W., 18 Feb 2021, In: Nature Communications. 12, p. 1-17 17 p., 1124. Carrier-free nanodrugs for safe and effective cancer treatment. Karaosmanoglu, S., Zhou, M., Shi, B., Zhang, X., Williams, G. R. & Chen, X., 10 Jan 2021, In: Journal of Controlled Release. 329, p. 805-832 28 p. Cation-free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy. Jiang, T., Qiao, Y., Ruan, W., Zhang, D., Yang, Q., Wang, G., Chen, Q., Zhu, F., Yin, J., Zou, Y., Qian, R., Zheng, M. & Shi, B., 11 Nov 2021, In: Advanced Materials. 33, 45, p. 1-10 10 p., 2104779. Chemical compounds with a neuroprotective effect from the seeds of Celosia argentea L. Guo, J., Shen, S., Zhang, X., Wang, G., Lu, Y., Liu, X., Wang, S., Li, Q., Cong, Y. & Shi, B., 7 Jan 2021, In: Food and Function. 12, 1, p. 83-96 14 p.